Genome (XKRX:314130) Land And Improvements : ₩2,710 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Genome Land And Improvements?

Genome's land and improvements for the quarter that ended in Dec. 2023 was ₩2,710 Mil.

Genome's quarterly land and improvements increased from Jun. 2023 (₩11 Mil) to Sep. 2023 (₩2,711 Mil) but then declined from Sep. 2023 (₩2,711 Mil) to Dec. 2023 (₩2,710 Mil).

Genome's annual land and improvements stayed the same from Dec. 2020 (₩0 Mil) to Dec. 2021 (₩0 Mil) but then increased from Dec. 2021 (₩0 Mil) to Dec. 2022 (₩11 Mil).

Genome Land And Improvements Historical Data

The historical data trend for Genome's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genome Land And Improvements Chart

Genome Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Land And Improvements

10.59

Genome Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Land And Improvements	Get a 7-Day Free Trial												10.59	10.90	10.97	2,710.70	2,710.24

Genome Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Genome (XKRX:314130) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486

Website

http://www.genomecom.co.kr

Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Genome (XKRX:314130) Headlines

No Headlines